VANCOUVER, BC / ACCESSWIRE / January 23, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is delighted to announce that it has appointed Dr. Stefan Hamill as Vice President, Strategy of the Company.

Dr. Hamill, based in London, was most recently with the UK-based mid and small-cap investment bank Numis, which he helped transform into the #1 corporate franchise in UK Life Sciences. During his career in capital markets he completed some of the most high-profile transactions in the sector. For more than a decade he was consistently ranked in the top three of UK Healthcare and Life Sciences analysts. He has a strong track record in identifying promising technologies and business models at an early stage and working to attract growth capital for Life Science companies throughout their lifecycle. Former clients include several billion-dollar-plus successes, such as life science research tools and diagnostics companies Abcam and Oxford Nanopore, the IP commercialisation firms Syncona, PureTech, IP Group and Oxford Science Enterprises, respiratory specialist Vectura and pharma services firms Clinigen and Ergomed. Dr. Hamill holds a PhD in biochemistry from the University of Cambridge and is a CFA charterholder.

Brian Firth, CEO of Gemina, commented "Gemina set a clear goal to strengthen its capital market resources in 2023. To be able to bring Stef into Gemina is a huge win for us. Stef is a specialist in identifying early stage healthtech companies and then supporting their management teams to deliver multi-billion-dollar success, on a global stage. We're very conscious that Stef had a plethora of choices when he decided to leave investment banking, and we're ecstatic that he has picked Gemina to be part of his future. We could not ask for higher quality guidance about how to design our relationship with the UK's sizeable healthtech and capital market communities."

Dr. Hamill responded, "I've been working with the Gemina team for several months now and have been impressed by the calibre of its management team and excited by the broad potential of its smart binding technology platform. I am keen to help Gemina fully explore the breadth of potential applications of its technology and to bring it to a global market - whether through licensing, where it has the potential to add value globally as technology inside partner products, or through commercialisation of Gemina's own product portfolio. Gemina has a fantastic opportunity to become a breakout success in the Life Sciences sector and I am delighted to be appointed as Vice President, Strategy."

On Behalf of the Board of Directors

John Davies
Chairman

Gemina Laboratories Ltd.

About Gemina Laboratories Ltd.

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can be found at .

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Forward Looking Statements

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the anticipated terms of any proposed transaction or engagement. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Furthermore, the Company is presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may affect planned or assumed performance moving forward. As such, any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

For more information regarding the Company, please contact:

Brian Firth, CEO
Email: investor@geminalabs.com

SOURCE: Gemina Laboratories Ltd.